SecBot SecBot
3 ·Filed Apr 1, 2026

GHRS

GH Research PLC
NEUTRAL
Impact 2/10
Horizonweeks Processed6mo ago SEC0001140361-26-012738
Form 3 — initial insider ownership statement
Actionable Insight • Neutral

Monitor future Form 4 filings for any insider transactions by Schonharting, as the Power of Attorney enables delegated share sales. No immediate trading implications, but increased transparency on ownership structure.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
GHRS ▲ +84.49% at T+60d
NEUTRAL call +84.49% · α vs SPY +70.33% · entry $14.57 → $26.88
Entry = T+0 close
Apr 1, 2026
via day close
T+1d
+3.91%
call +3.91% · α +3.44%
$15.14
settled 7mo ago
T+5d
+7.89%
call +7.89% · α +4.27%
$15.72
settled 7mo ago
T+20d
+40.91%
call +40.91% · α +31.03%
$20.53
settled 6mo ago
T+60d
+84.49%
call +84.49% · α +70.33%
$26.88
settled 4mo ago

Price Chart

Loading chart...

Executive Summary

Florian Schonharting, a reporting person at GH Research PLC, filed a Form 3 to report initial beneficial ownership of 14,824,419 ordinary shares and appointed five individuals as attorneys-in-fact to handle SEC filings and potential share sales on his behalf. This is a routine compliance filing with no immediate financial impact.

Key Facts

  • Florian Schonharting holds 14,824,419 ordinary shares in GH Research PLC
  • Filed Form 3 to report initial beneficial ownership as of April 1, 2026
  • Appointed five individuals (Louise Barrett, Rannagh Morris, Julie Ryan, Magnus Halle, Emma Corcoran) as attorneys-in-fact to execute Forms 3, 4, 5, and Form 144 on his behalf
  • Power of Attorney granted on March 6, 2026, allows for potential future share sales under Rule 144

Financial Impact

No immediate financial impact. Potential for future share sales exists but not quantified.

insider ownershippotential dilutioninsider selling

Risk Factors

  • Potential for future insider selling under Rule 144, which could create downward pressure on stock price
  • Lack of disclosure on whether the shares are held directly or indirectly, affecting ownership clarity

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
3 Filing (Primary)0001140361-26-012738
Document: 0001140361-26-012738-index-headers.html0001140361-26-012738
Document: 0001140361-26-012738-index.html0001140361-26-012738
Document: 0001140361-26-012738.txt0001140361-26-012738
11 reports for GHRS
Performance horizon
67% Hit rate @ T+5 4 of 6 directional calls Went positive at some point 4 of 6 best @ T+60▲ +63.68%Mar 5, 2026
Filters
Rows
Reports for GHRS — sortable, filterable
TypeNow
Oct 9, 2026
17d ago
6-K
NEUTRAL ★ 2/10
$21.11 $18.15▼ −14.02%▼ −12.05%$19.16 (−9.24%)
Sep 11, 2026
6w ago
6-K
NEUTRAL ★ 2/10
$27.20 $28.26▲ +3.90%▲ +4.12%$19.16 (−29.56%)
Aug 6, 2026
11w ago
6-K
BULLISH ★ 7/10
$30.64 $28.19▼ −8.00%▼ −9.21%$19.16 (−37.47%)
May 14, 2026
23w ago
424B5
BEARISH ★ 6/10
$22.21 $21.77▲ +1.98%▲ +1.26%$19.16 (+13.73%)
May 14, 2026
23w ago
6-K
NEUTRAL ★ 5/10
$22.21 $21.77▼ −1.98%▼ −1.26%$19.16 (−13.73%)
May 14, 2026
23w ago
Press Release
MIXED ★ 6/10
$22.21 $21.77▼ −1.98%▼ −1.26%$19.16 (−13.73%)
May 13, 2026
23w ago
6-K
BEARISH ★ 6/10
$22.21 $21.77▲ +1.98%▲ +1.26%$19.16 (+13.73%)
Apr 29, 2026
25w ago
424B5
BEARISH ★ 6/10
$19.16 $21.28▼ −11.06%▼ −7.95%$19.16 (+0.00%)
Apr 1, 2026
29w ago
3
NEUTRAL ★ 2/10
$14.57 $15.72▲ +7.89%▲ +4.27%$19.16 (+31.50%)
Mar 25, 2026
30w ago
Press Release
BULLISH ★ 8/10
$13.65 $14.72▲ +7.84%▲ +8.08%$19.16 (+40.37%)
Showing 10 of 11

US Market Status

Market Open — Closes in 6m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 1, 2026